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COMPARISON OF MANAGEMENT AND TREATMENT OPTIONS FOR 
RECURRENT BREAST FIBROADENOMA IN FEMALE ADOLESCENTS 
ALISHA SHERWANI 
ABSTRACT 
  
 Breast fibroadenomas account for approximately 25% of all lesions in 
asymptomatic women, resulting in large health care costs every year. There are 3 
different variations of the disease: simple, juvenile giant and multiple. Patients may have 
different management and treatment options available to them depending on which 
variation they have. Of particular interest are female adolescents, who are at most risk for 
developing these lesions. With this age group not only is it important to pursue options 
that are minimally invasive and effective, but there are psychosocial implications to 
consider regarding the cosmetic changes that may occur with the disease, as well as 
generalized anxiety over having a breast lump. These issues are important to consider for 
physicians when recommending a treatment or management option. After a systematic 
review of all options available, it appears the best management method is the 
conservative treatment as it minimizes invasive intervention and operates on the principle 
that 10-40% of lesions regress on their own; however, there may be times that 
adolescents are uncomfortable with this treatment due to anxiety and other uneasiness 
about having a lesion remain in their breasts, despite the low chance of malignancy 
associated with breast fibroadenomas. Minimally invasive procedures are being 
developed in order to minimize possible iatrogenic injury to the developing breasts as 
  vi 
well as maintain efficiency and good cosmesis post-procedure. Cryoablation is a 
minimally invasive technique utilizing extreme cold temperatures for lesion excision that 
is not currently widely used, however it has great potential to replace traditional open 
surgical excision.   
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INTRODUCTION 
 Benign breast lesions are one of the most common growth disorders in women 
(Duflos, Plu-Bureau, Thibaud, & Kuttenn, 2012). The most common lesions in this 
category are fibroadenomas, accounting for nearly 25% of women (El-Wakeel & 
Umpleby, 2003). In adolescent females this number is even higher, ranging between 
54%-94% of all cases (Ezer et al., 2013) It is second only to carcinoma in overall 
frequency of breast tumors (Nagasue, 2002), signifying its clinical relevance. 
Fibroadenomas are defined by Guray & Sahin (2006) as a palpable breast mass that may 
be mobile and firm, often palpable under the skin. They are usually unilateral in 90% of 
the cases (C. A. Park, David, & Argenta, 2006) however it may be present bilaterally and 
may be either singular or multiple per breast (ACS, 2015). They can range in size from 
less than 5cm to larger, with the largest ones, typically seen as a giant juvenile 
fibroadenoma, greater than 10cm during puberty or pregnancy (Santen, 2000). 
Macroscopically, fibroadenomas are well-circumscribed with the excised lesion 
appearing characteristically lobulated and bulging (Guray & Sahin, 2006). 
Microscopically, fibroadenomas consist of a proliferation of connective and epithelial 
tissue. The stroma proliferates around tubular glands or compressed cleft-like ducts 
(Guray & Sahin, 2006). Both views can be seen in figure 1.  
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Figure 1: Breast Fibroadenoma. (A)This depicts an excised fibroadenoma. Note the 
gray-white color and size, ranging from 14-17cm, indicating that this is perhaps a 
juvenile giant fibroadenoma. (B) Microscopic view of a fibroadenoma. Note the 
compressed cleft-like ducts. (Figure from Guray & Sahin, 2006).  
 
 
The peak age of incidence is between the ages of 15-35 (Guray & Sahin, 2006), 
further emphasizing the role of fibroadenomas on adolescent life. Especially important to 
the adolescent age group are the associated psychosocial implications of this disease, 
such as psychological and physical embarrassment, as it is mainly viewed as a cosmetic 
disease due to the low chance for malignancy (Duflos et al., 2012). This, in combination 
to its prevalence, is why it is critical for physicians to be aware of the various 
management options and treatments currently available and recommended, as well as 
which is most cost-effective for the patient’s individual type and size of fibroadenoma 
(Jayasinghe & Simmons, 2009). 
 3 
 
Palpation, breast imaging and biopsy are currently the methods used to monitor 
fibroadenomas, with treatment options including surgical removal, vacuum-assisted core 
biopsy (VACB), ablation and a more conservative observation approach.   
 
Monitoring Options 
 Discovery of the breast lumps is typically first done via physical palpations, either 
by the physician finding them during routine breast exams or the patient themselves 
discovering the lumps with self-examinations or simply feeling a difference in their 
breasts. These palpations are used, along with sonography and biopsy to determine 
whether it is indeed a fibroadenoma, other benign breast tumor, or possibly, albeit rare in 
adolescents, breast cancer (Greenberg, Skornick, & Kaplan, 1998a).  
 Imaging is used as a next step upon finding an unidentifiable breast mass. 
Mammography is known to be the most informative, however since the high adolescent 
breast density interferes with detection of masses, mammography is not recommended for 
this age group (Chung et al., 2009). Instead ultrasound (US) is the most efficient method 
of imaging, and is rapidly becoming the imaging method of choice for certain procedures 
or biopsies. Upon observing the mass, or masses in case of multiple, there may be a 
biopsy procedure done to confirm the nature of the lesion if anything appears to be 
suspicious. This is typically done in adolescents due to patient or family member anxiety, 
however if a breast mass is shown to be benign via imaging and following other strict 
criteria, there may not be a need for biopsy and instead the physician will recommend 
less invasive monitoring, such as the conservative method (Jawahar, Vade, Ward, Okur, 
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& Subbaiah, 2015). According to the study done by Jawahar et al. (2015), any change in 
dimension, volume, or appearance in sonography must be recorded in order to determine 
whether or not biopsy should be performed to confirm identification of the mass.   
 
Treatment Options 
 Due to the predominately benign diagnosis of a breast tumor, or fibroadenoma in 
particular, there have been recent controversies over which treatment is most effective 
(Ezer et al., 2013). As Ezer et al.(2013) explains, due to a variety of opinions, the 
ultimate decision is up to the patient and their family on which route they prefer. One 
method is conservative management, in which there are frequent sonography checkups to 
monitor the tumor for growth and no other invasive procedures done (Greenberg et al., 
1998a). The decision to pursue this method is supported the knowledge that 
approximately 10-40% of masses regress completely after a certain period of time 
(Jayasinghe & Simmons, 2009; Neinstein, Atkinson, & Diament, 1993). The procedure 
that dominates the field at the moment is surgical removal of the tumor, also known as a 
lumpectomy (Kaufman et al., 2002). As noted by Kaufman et al., (2002) this method is 
not the most ideal due to its longer recovery stage, potential for cosmetic scarring and the 
daunting task of undergoing surgery. The current direct alternative is vacuum-assisted 
biopsy, in which tumors up to 3cm may be removed with less cosmetic damage 
(Kolkman & Zonderland, 2011). This is achieved with a cannula under the guidance of 
US, though it requires sedation and can often be difficult to remove the entire 
fibroadenoma, leading to recurrent cases if there is any malignancy involved (Nurko et 
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al., 2005). Newer studies on cryoablation have been shown to be cost-effective 
alternatives to current convention, though there is a long follow-up time, particularly for 
the larger mass sizes (Nurko et al., 2005).  
 There may be times where one or more new fibroadenomas grow after one is 
removed (ACS, 2015), leading to another important factor to be considered when 
different treatment modalities are considered: chance of recurrence. While this recurrence 
is typically due to a new formation or growth of pre-existing fibroadenoma, and not 
regrowth of the previously excised lesion (ACS, 2015), it can still mean multiple 
treatments for a patient. For adolescents, this may mean continuous surgeries, biopsies or 
other treatments that may impede normal developmental growth of the breast buds. Even 
the least invasive methods still have a chance for iatrogenic injury, as well as 
psychosocial complications for the multiple treatments. The focus of this thesis therefore 
is to look into the most cost-effective options available for such cases in adolescents, 
while also paying special attention to patient satisfaction and chance for cosmetic defects.  
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SPECIFIC AIMS AND OBJECTIVES 
 There are a number of treatment options available for fibroadenomas that 
need to be considered for adolescents, particularly because of the patient’s young age. 
The focus of this thesis is to pinpoint which options are more cost-effective and catered 
to the younger population by analyzing the existing practices.  
 
 The specific aims of this thesis are to:  
1. Identify key components of the different types of adolescent 
fibroadenomas and their importance, such as the risk factor for 
future malignancy, cosmetic damage, and the psychosocial 
implications specific to this age group. 
2. Evaluate the current Breast Imaging- Reporting and Data System 
(BI-RADS) system of classification for fibroadenomas and how 
the system corresponds to adolescents, as well as assess available 
treatment methods and current recommendations regarding the 
individual categories of classification.   
3. Assess the various management methods in the following 
categories: accuracy in diagnosis, cost-effectiveness, patient 
compliance, and cosmetic damage and patient satisfaction.  
4. Assess the various treatment methods in the following categories: 
cost-effectiveness, accessibility of treatment, chance of recurrence, 
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undesirable elements, cosmetic damage and patient satisfaction, 
and cosmesis.  
5. Determine the most effective treatment and management methods 
to date for the various types of fibroadenomas in adolescents and 
what future procedures might improve upon. 
 
The goal of this literary review is to assess the available management 
options and treatments and determine which of the options might most effectively 
treat the disease in female adolescents.   
 8 
 
FIBROADENOMA BASIC INFORMATION 
Fibroadenomas develop from the stroma of the mammary gland lobule (Figure 2) 
and, due to their typical superficial locations in the breast, are often palpable (ACS, 
2015). During breast examination the patient, or provider, may press in the area and feel a 
firm, spherical mass that appears rubbery and non-tender (Guray & Sahin, 2006). Patients 
may report it feels like a marble within the breast that you can freely move around under 
the skin (ACS, 2015), a helpful indicator for providers upon initial consultation.  In up to 
20% of the cases there may be multiple palpable lesions in a single breast or even several 
on both sides (Guray & Sahin, 2006).  
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Figure 2: Simplified Anatomy of the Female Breast and its Lesions. Due to their 
spherical shapes and similar locations, fibroadenomas and cysts are often suspected 
together upon palpation of an abnormal mass. Typically imaging or histology can 
differentiate between the two as cysts are fluid-filled and fibroadenomas are solid. 
(Figure from Santen, 2000).  
 
 The exact etiology of fibroadenomas is currently unknown; however there are 
many speculations in literature that it may be related to changes in the levels of 
reproductive hormones. To begin with, fibroadenomas are typically detected during the 
early stages of reproductive life when these hormones play vital roles in development 
(Matz et al., 2013). Epithelial components within the lesion have also been shown to be 
hormone responsive, as they are stimulated by various factors including estrogen, 
progesterone, pregnancy, and lactation (Santen, 2000). Fibroadenomas are known to 
expand in size during the menstrual cycle (Cerrato & Labow, 2013; Lee & Soltanian, 
2015), lactate during pregnancy, and shrink with the rest of the breast in perimenopause 
(El-Wakeel & Umpleby, 2003; Hughes, Mansel, & Webster, 1987). Despite the influence 
of estrogen on fibroadenomas, conservative therapy with progesterone and danazol does 
not work as the fibroadenomas fail to respond to the antiestrogen medications 
(Greenblatt, Nezhat, & Ben-Nun, 1980). Aside from the reproductive hormones, studies 
have also shown that fibroadenomas may also be linked to body mass index (Lee & 
Soltanian, 2015) and underlying or acquired genetic components (Santen, 2000). Further 
investigation is underway to pinpoint more definitive causes, however at this time they 
are not preventable.  
 As of now there are two types of fibroadenomas, simple and giant juvenile 
fibroadenomas (Cerrato & Labow, 2013). Both of these types may be either singular or 
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multiple, leading to a separate class known in literature as multicentric fibroadenomas. 
Simple fibroadenomas are the most common type and account for approximately 70-90% 
of all cases (Lee & Soltanian, 2015). Giant juvenile fibroadenomas are rare, only 
accounting for approximately 0.5-8% of cases (Divasta et al., 2012; Lee & Soltanian, 
2015) and typically occurring in earlier ages.  Multicentric fibroadenomas account for 
approximately 10-25% of all cases, and have no specific age range of its own. Each case 
varies from individual to individual, and similarly the treatment and management options 
vary depending on the types. 
 
Simple Fibroadenoma 
 Simple fibroadenomas are, as their name suggests, the most basic type in terms of 
composition and management. Simple fibroadenomas are not associated with any risk of 
breast cancer (Guray & Sahin, 2006) and is therefore most often watched conservatively. 
If there are any significant changes in size or composition over time, the fibroadenoma 
may be biopsied, however this is quite rare.  Typically these fibroadenomas remain static 
at 2-3cm in size; however they may spontaneously regress or enlarge regardless of 
hormonal factors (Guray & Sahin, 2006). For a simple fibroadenoma 10-40% of cases 
result in complete regression without any sort of intervention (Jayasinghe & Simmons, 
2009; Neinstein et al., 1993) which is another reason why conservative treatment is the 
commonly used pathway for this type. Aside from rapid enlargement, suspected 
malignancy or symptoms including pain in rare cases, the only reason for surgical 
intervention in this type is due to patient or family member anxiety, despite the fact that 
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there is less than a 1% chance for malignancy (Lee & Soltanian, 2015). This is especially 
true in the adolescent population, for which this type is most commonly seen. There is 
typically little change in outward appearance of the breasts for this type, as they are too 
small to be seen in even the early developmental stages; however there have been cases 
reported where the fibroadenoma was so superficial it was visible as a lump protruding 
from the skin.  
 
Multiple Fibroadenoma 
 Multiple fibroadenomas typically occur with the simple type; multiple giant 
fibroadenomas are rare and mainly occur in adolescent and young adult African 
American females (Musio, Mozingo, & Otchy, 1991). There appears to be a strong 
genetic component in the majority of reported cases in both multiple giant fibroadenomas 
and multiple simple fibroadenomas (Williamson, Lyons, & Hughes, 1993). There are 
usually only one or two fibroadenomas unilaterally, however there have been cases 
reported with multiple bilaterally or even up to four in a single patient (Williamson et al., 
1993). The chance for malignancy in this type may be higher than simple fibroadenomas 
though an exact determination has yet to be identified.  Due to the spontaneous changes 
in size of fibroadenomas, it is not inconceivable that after an enlarged lesion is removed, 
one of the previously small lesions may grow to an uncomfortable size and require more 
intervention. While there is little cosmetic damage to the breast in this type, as with 
simple fibroadenomas, after multiple surgical interventions or biopsies there may be 
iatrogenic injury. For this reason most multiple fibroadenomas are watched 
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conservatively until a reason to remove them arises. In adolescents there may be cause 
for anxiety; however surgical intervention is less likely due to its chance of recurrence.  
 
Juvenile Giant Fibroadenoma 
 Juvenile fibroadenoma is a variant of simple fibroadenoma that presents earlier in 
adolescents at the onset of puberty, typically between 10 and 18 years of age, and are 
usually painless, solitary, and unilateral masses greater than 5cm in size (Guray & Sahin, 
2006; Ng, Mrad, & Brown, 2011). They are usually located in the outer upper quadrant of 
the breast (Thuruthiyath, Das, Avabratha, Mascarenhas, & Marla, 2012) and are the most 
common cause of unilateral enlargement of the breast tissue in excess of normal 
proportion, also known as macromastia, in adolescents (Musio et al., 1991). Juvenile 
giant fibroadenomas are rapidly growing lesions with associated skin ulcerations, 
erythema, venous engorgement, and stretched overlying skin (Chepla, Armijo, Ponsky, & 
Soltanian, 2011; Divasta et al., 2012).  Other changes can include both stretching of the 
areola complex and distortion of the dermal tissue underneath (Matz et al., 2013). They 
compress adjacent tissue, distort lobular architecture, and create pea d’orange, nipple 
inversion, and skin dimpling (C. A. Park et al., 2006). Unlike the simple fibroadenomas, 
giant fibroadenomas are often associated with significant cosmetic damage and, 
consequently, psychosocial implications. Giant fibroadenomas are known to cause 
unpleasant interactions with the patient’s peers and have a considerable impact on self-
esteem, confidence and other psychological and emotional states (Sosin et al., 2015). 
Interestingly, if there is minimal cosmetic change between the breasts aside from the 
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enlarged size patients report in initial consultation they believe the contralateral, smaller 
breast is the problem. They are relatively at ease with the pathologically enlarged breast, 
particularly if there is significant difference in size between the two (C. A. Park et al., 
2006).  It is therefore important they are referred to a specialist with experience in this 
field to facilitate a more focused evaluation and treatment strategy incorporating the 
psychosocial and sensitive elements involved (Sosin et al., 2015). Figure 3 illustrates a 
case in which the patient may have preference to the larger breast, as there is little 
difference aside from the size of the areola complex. 
 
Figure 3: Juvenile Giant Fibroadenoma Present in Adolescent Female. Adapted from 
(C. A. Park et al., 2006).  
 
Aside from outward appearance, there is also significant concern from the patient 
or their family regarding the malignant potential or altered breast development due to 
these giant fibroadenomas (Chepla et al., 2011). This is not unwarranted, as it has been 
shown that giant fibroadenomas are considered indicators of malignancy and almost 
always biopsied (Neinstein, 1999). Malignancy is not the only reason giant juvenile 
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fibroadenomas are biopsied initially; giant fibroadenomas have a tendency to compress 
and possibly replace normal breast tissue, causing the giant fibroadenoma to be confused 
for normal tissue (Choo et al., 2008). As a result, it is difficult to differentiate between a 
giant fibroadenoma and juvenile hypertrophy without histologic evidence, even with 
imaging. The only other helpful indicator is that juvenile hypertrophy is typically 
bilateral and even (Divasta et al., 2012). Figure 4 shows an MRI image taken of a 
juvenile giant fibroadenoma. If possible, note in 4A the faint lines outlining the 
fibroadenoma; this can be difficult to detect in an untrained eye without T2-weighting to 
enhance the septations and encapsulation, which is shown in 4B. There it is easier to see 
the encapsulated fibroadenoma and the differences in composition between the lesion and 
surrounding tissue that would otherwise be difficult to tell apart. Of interest, with the T2-
weighted image (4B) it is also clear to see how severely the surrounding normal breast 
tissue has been compacted and replaced by the lesion.  
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Figure 4: MRI Image of Juvenile Giant Fibroadenoma. (A) Baseline MRI image. (B) 
T2-weighted image of the same breast. Adapted from (C. A. Park et al., 2006). The white 
arrow points to normal breast tissue, while the black arrow points to the center of the 
lesion. 
 
Another lesion that is often confused with giant fibroadenomas is the phyllodes 
tumor. Breast phyllodes tumors do not typically present in adolescents, as they arise 
during the ages of 35-55 (Celik et al., 2015), however it is not impossible. They are 
similar to giant fibroadenomas; however they have increased cellularity and tendency to 
recur and metastasize (Celik et al., 2015). Phyllodes tumors are often associated with 
malignancy, particularly if the lesion is as large as giant fibroadenomas, so differentiating 
the pathology is important prior to surgical excision (Celik et al., 2015; Sosin et al., 
2015). Table 1 illustrates the macroscopic and microscopic differences between simple 
fibroadenomas, juvenile giant fibroadenomas and phyllodes tumors. Note the 
macroscopic similarities necessitate microscopic evaluation to differentiate between the 
juvenile giant fibroadenoma and the benign phyllodes tumor.  
Table 1: Comparison of Fibroadenomas and Phyllodes Tumors. Adapted from 
Méndez Ribas, 2010. 
 
 Macroscopic Microscopic 
Simple Fibroadenoma Pseudo-capsule 
Bright white clefts 
Fibrous connective tissue 
Proliferation of variable 
ducts and acini 
Juvenile Giant 
Fibroadenoma 
Pseudo-capsule 
Pale brownish-grey clefts 
Foliaceous 
Relaxed connective tissue 
Abundant proliferation 
ducts and acini 
Benign Phyllodes Well delimited 
Brownish-grey clefts and 
cavities 
Foliaceous aspect 
Aberrant fibro-plastic 
connective tissue with mild 
atypia and scarce mitosis 
Dilated ducts 
Malignant Phyllodes Irregular contour Connective tissue featuring 
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Large brownish-grey clefts 
and cavities 
atypia and mitosis 
Adjacent tissue infiltration 
Duct proliferation 
 
 
 Once biopsied and diagnosed, juvenile giant fibroadenomas are benign lesions 
that may reach up to 15 or 20cm in size (Carter et al., 2001). The treatment options vary, 
though general consensus until this point has been surgical excision with subsequent 
reconstruction of the remaining breast (Celik et al., 2015). Due to the potentially large 
size of the lesion (figure 5) and resulting asymmetry of the breasts, aesthetic 
reconstruction can be difficult to achieve to patient satisfaction (C. A. Park et al., 2006). 
Depending on the situation, conservative measures or subcutaneous mastectomy may also 
be appropriate, however not as commonly used. There have been reports of recurrence 
after complete excision of the lesion, though this chance drops to a negligible level after 
the patient reaches the age of 30 (Thuruthiyath et al., 2012). Due to the extent of tissue 
distortion large juvenile giant fibroadenomas cause there are limited options for 
treatment, despite the emergence of new techniques.  
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Figure 5: Excised Juvenile Giant Fibroadenoma in Adolescent Female. Image from 
(C. A. Park et al., 2006). 
 
 Although not as common in adolescents, lesions with indwelling calcifications or 
other complications are termed ‘complex fibroadenomas.’ Complex fibroadenomas may 
occur in fibroadenomas of all types, and are associated with increase in chance of 
malignancy development, higher levels in categorization per the BI-RADs classification, 
and it may alter the means of biopsy or treatment as certain techniques are limited in their 
ability to assess calcifications. In particular, giant juvenile fibroadenomas that are 
complex are subjected to surgical excision immediately due to their increased risk of 
malignancy development. There still exist little other options for excision of complex 
fibroadenomas, particularly for the giant type.  
 
Calcifications 
Breast calcifications refer to calcium deposits within breast tissue that are not 
identified without radiographic imaging, in which they appear as white spots or flecks 
(Mayo Clinic, 2016). Calcifications typically arise after menopause, during which a 
lesion that has regressed will often leave behind a fibrous mass that may calcify (Hughes, 
1991; Mayo Clinic, 2016). Calcifications are therefore uncommon in adolescents (G. M. 
Tse, Tan, Pang, Tang, & Cheung, 2008); however, there have been cases where 
fibroadenomas in adolescents contain calcifications. Calcifications may be formed in two 
different ways: secretory type and necrotic type. In the secretory type the calcium that are 
released by the surrounding breast tissue cells accumulates, which is most often seen in 
 18 
 
benign lesions or low-grade malignancies (Gary M. Tse, Tan, Cheung, Chu, & Lam, 
2008). The necrotic type is associated with rapidly proliferating tumor cells that are 
depleted of their vascular supply. The necrotic type is typically associated with 
malignancy (Gary M. Tse et al., 2008).   
Calcifications are also classified based on size and shape.  Macrocalcifications are 
benign, scattered over a large area and appear as smooth, round and dense objects on 
mammogram (Muttarak, Kongmebhol, & Sukhamwang, 2009; G. M. Tse et al., 2008). 
Calcifications typically seen within shrinking fibroadenomas in particular are coarse, or 
“popcorn” shaped calcifications that are totally benign (G. M. Tse et al., 2008). 
Malignant calcifications, or large necrotic types, appear in clusters or with linear 
morphologies that can be large and pleomorphic (Muttarak et al., 2009; G. M. Tse et al., 
2008). Microcalcifications are also typically benign; however they have been associated 
with the start of cancer (Mayo Clinic, 2016). Studies have shown that the number of 
calcifications per area is also important in indicating malignancy, where calcifications 
that are clustered tightly together are more likely to be malignant (Egan, McSweeney, & 
Sewell, 1980; J. M. Park et al., 2000; Powell, McSweeney, & Wilson, 1983). 
 The traditional way to visualize calcifications is through mammogram as they are 
poorly characterized in US; however, with the development of high-frequency, high-
resolution modern transducers calcifications may be recognized as echogenic foci within 
fibroadenomas or other masses in ultrasound (ACR, 2013). These modern transducers 
have the ability to depict intraductal calcifications that are superficial, as well as groups 
of microcalcifications when concentrated in fibroglandular tissue (ACR, 2013). These 
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transducers allow a way to characterize calcifications in adolescents using ultrasound; 
however, when adults are given an option mammogram is still the preferred method. 
 
Complex vs. Non-Complex 
Approximately 50% of simple fibroadenomas may contain some other sort of 
proliferative change in the breast tissue such as adenosis, calcifications, duct epithelial 
hyperplasia, florid fibrocystic disease, and sclerosing adenosis (Guray & Sahin, 2006; 
Shabtai et al., 2001). These fibroadenoma-associated pathology complexes are classified 
as complex fibroadenomas. The average age of patients with complex fibroadenomas, 
around 47 years, is significantly higher than that of non-complex fibroadenomas, 
approximately 28.5 years (Ohashi et al., 2015). While very rare in adolescents, complex 
fibroadenomas have been linked to slightly higher risk for subsequent cancer (Carter et 
al., 2001). The literature for complex fibroadenomas is still limited, particularly in 
comparison to non-complex fibroadenomas, however the complex phenotype has been 
universally classified in the Breast Imaging-Reporting and Data System (BI-RADS) as an 
immediate category 4, or ‘suspicious,’ due to its link to malignancy. As with all other 
category 4 lesions, biopsy is strongly recommended. If the sample confirms the 
fibroadenoma to be complex, the most common next step will be surgical excision.  
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LESION CLASSIFICATION SYSTEMS 
In order to facilitate communications between providers and unify treatment 
options globally, classification systems were devised. The most commonly used is the 
Mammography BI-RADS system developed by the American College of Radiology 
(ACR). For adolescents there is a similar Ultrasound BI-RADS system that was recently 
developed, as mammography is not useful in adolescents due to their dense breast mass. 
These two classification systems are used after imaging to classify the extent of disease. 
The categories are used to determine which treatment option is best, as well as the chance 
of malignancy. The BI-RADS system runs from category 0 to category 6, with category 6 
being the most malignant. In order better classify benign breast lesions in regards to their 
etiology and location, the Aberrations of Normal Development and Involution (ANDI) 
classification system was developed. The ANDI classification system was first published 
in 1982, though a finalized table including all of the known lesions was not published 
until 1991 (Hughes, 1991).  
 
ANDI Classification 
 The ANDI classification allows adjustments in therapeutic strategies between 
conservative and aggressive options (Duflos et al., 2012) depending on whether the lesion 
is classified as ‘benign,’ ‘aberrant,’ or ‘disease.’ One of the reasons this classification was 
developed was to incorporate fibroadenomas as an option, as the fibroadenoma presents 
features different than that of most benign tumors (Hughes, 1991). Simple fibroadenomas 
of small, non-palpable size are considered benign while palpable simple fibroadenomas, 
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or multiples of 3 or less, were instead considered an aberration of normal lobule 
development rather than a true neoplasm (Duflos et al., 2012; Hughes, 1991; Hughes et 
al., 1987). Multicentric, simple fibroadenomas of more than 5 or juvenile giant 
fibroadenomas were both placed on the ‘disease’ end of the spectrum and thus treated 
more aggressively (Duflos et al., 2012; Hughes, 1991). An example of the ANDI 
classification table is shown in figure 6. Reading from the left, there is a column with the 
3 reproductive periods: early (adolescence), middle, and late. Next is a column containing 
the 3 main breast components: glandular, ductal, and stromal elements divided within 
each reproductive period. Throughout each breast component within its respective 
reproductive period are the separations between normal development, aberrant 
development and disease. Of interest is the glandular component in the early reproductive 
period containing the fibroadenoma. 
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Figure 6: ANDI Classification of Benign Breast Lesions. Figure from Hughes et al., 
1987.  
 
 Excess cyclical hormonal stimuli to the glandular component of the breasts as 
seen in the menstrual cycle of the early reproductive period in females have been shown 
to be a cause for fibroadenoma development (Santen, 2000). The lobules grow to a larger 
size than normal, forming fibroadenoma that may change in size from slightly abnormal 
to large, palpable lesions (Santen, 2000).  
 
Mammography BI-RADS 
 Mammography is the most common form of imaging for breast lesions. As a 
result, the ACR developed the BI-RADS system in order to universally describe 
mammogram findings and results (ACS, n.d.). It ranges from category 0, which indicates 
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a palpable lesion as detected via breast examination but the imaging has not yet taken 
place or there are no prior exam results, to category 6 that indicates known breast cancer 
or malignancy. For women over 35 this is the preferred method as it is more detailed, 
precise and comprehensive. 
 
Ultrasound BI-RADS 
 Ultrasound BI-RADS was recently developed for adolescents and other groups 
that are unable to undergo mammography. The system follows the same categories and 
criteria as the mammogram BI-RADs system however it is more specialized to what is 
visualized in ultrasound versus what is seen in mammography. The patient would 
undergo an ultrasound procedure and depending on what was visualized, a category is 
assigned to that patient’s lesion and noted in the chart for subsequent encounters. The 
categories are useful in determining the most appropriate path of management or 
treatment, though the final decision is ultimately up to the patient and their family 
members.  
Category 0: Prior to Imaging 
 This category is used prior to imaging or if additional imaging or prior 
examinations are required (ACS, n.d.). This category is almost never utilized as imaging 
is done almost immediately after the discovery of a possible palpable lesion.  
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Category 1: Negative 
 This category is reserved for when there are no lesions found during either routine 
ultrasound imaging for a different reason, or per patient request. There is no management 
or treatment options necessary for this category, instead routine follow-up should 
continue for developing changes. 
Category 2: Benign 
 In this category a lesion was found, however there are no apparent malignant 
features and is therefore classified as benign. This includes diagnoses such as simple 
cysts, intra-mammary lymph nodes, breast implants, stable postsurgical changes and 
simple fibroadenomas that are noted to be stable on successive US studies for a period no 
less than 2 years (ACR, 2013). The fibroadenomas also need to be of small size and be 
non-complex.  
Category 3: Probably Benign 
 This category is used for solid masses with circumscribed margins, oval shapes, 
and horizontal orientations that are most likely to be fibroadenomas. This is also used for 
isolated, nonpalpable complicated cysts that have a likelihood of malignancy in the less 
than 2% range, as well as clustered microcysts (ACR, 2013). Suggested management 
includes either biopsy or initial short-interval follow-up of approximately 6 months 
where the study will be repeated to observe for any changes (ACR, 2013). 
Fibroadenomas that continue to be stable are re-classified as category 2 after the 2 year 
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mark. Biopsy is ideally avoided in favor of the more conservative approach; however in 
adolescents it may be requested by the family to confirm the diagnosis of the lesion. 
Category 4: Suspicious 
 This category is used for lesions that show malignant properties such as those 
seen in complex fibroadenomas; however it is not necessarily indicative of cancer. There 
is, however, a chance for cancer of upwards to 94%, indicating a strong recommendation 
for biopsy, particularly in women older than 35 (ACR, 2013). Included in this category 
are sonographic findings of a solid mass without all the criteria for a fibroadenoma or any 
other benign lesions (ACR, 2013) such as irregular outlines or abnormally large size. 
Until a biopsy is done to confirm the diagnosis, a juvenile giant fibroadenoma will fall 
into this category.  
Category 5: Highly Suggestive of Malignancy 
 This category is used when the lesion is almost certainly cancer, with a 95% 
chance (ACR, 2013). Masses with irregular, difficult to define boundaries and very dark 
centers in US are typically indicative of cancer. Patients with these types of masses are 
immediately sent for biopsy and appropriate actions are taken from there, including most 
likely surgical excision. It is quite rare for an adolescent to be in this category, as they are 
of low risk for cancer or other malignancies; however there have been cases where this 
has happened. 
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Category 6: Known Malignancy 
 This category is used for a lesion that has already been biopsied and confirmed to 
be cancer. It will remain a category 6 until it is surgically excised, or prior to the 
institution of therapy. As with category 5, it is rare for an adolescent to be in this stage.  
 
Table 2: Ultrasound BI-RADS Assessment Categories. Created using information 
from Zonderland & Smithuis, 2013. 
 
Category Management 
Likelihood of 
Cancer 
0 
Need additional imaging or prior 
examinations 
Recall for additional 
imaging and/or await 
prior examinations 
N/A 
1 Negative Routine Screening Essentially 0% 
2 
Benign Routine Screening 
for age, possible 
conservative 
management 
Essentially 0% 
3 
Probably Benign Short interval 
follow-up (6 months) 
or tissue diagnosis 
More than 0% but 
less than 2% 
4 
Suspicious 
Category 4A: Low suspicion for 
malignancy 
Category 4B: Moderate suspicion 
for malignancy 
Category 4C: High suspicion for 
malignancy 
Tissue diagnosis 
strongly 
recommended 
More than 2% but 
less than 95% 
4A: More than 2% 
but less than 10% 
4B: More than 
10% but less than 
50% 
4C: More than 
50% but less than 
95% 
5 
Highly suggestive of malignancy Tissue diagnosis 
required 
More than 95% 
likelihood of 
malignancy 
6 
Known biopsy-proven malignancy Surgical excision 
when clinically 
appropriate 
N/A (100%) 
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 Table 2 above summarizes the ultrasound BI-RADS assessment categories. The 
mammography BI-RADS categories are nearly identical, with the difference being the 
criteria in which the decisions are made based on mammographic findings instead of 
sonographic findings. Note category 4 is split into 3 parts in the mammography BI-
RADS: 4A, 4B, and 4C indicating low suspicion (2-10%), moderate suspicion (11-50%) 
and high suspicion (51-94%) in order. This is because of the large range of possible 
malignancy between 2% and 94%. With these subdivisions more targeted strategies and 
treatments may be employed. Juvenile giant fibroadenomas typically fall into the 4A 
category.  
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EVALUATIONS OF MONITORING OPTIONS 
 Unless there are underlying comorbidities or symptoms that warrant imaging of 
the breasts, the first clue to the appearance of a fibroadenoma is a palpable mass that 
either the patient feels or the physician finds during routine breast examinations. Upon 
finding the mass, the previous recommendations called for what was called ‘The Triple 
Test,’ which included palpation, imaging and percutaneous biopsy (Santen, 2000). With 
the emergence of the conservative method, current recommendations, particularly for 
younger females, include palpation and ultrasound imaging to evaluate the characteristics 
of the lesion for benign findings. If it meets criteria to be classified as benign, or 
‘probably benign’ in the category 3 of BI-RADS, standard practice at this time is to 
follow the lesion conservatively with annual or bi-annual ultrasound imaging (Graf et al., 
2004). If after approximately 2-3 years, a stable fibroadenoma will be re-classified as a 
category 2 lesion in BI-RADS, or ‘benign.’ 
 
IMAGING 
 Traditionally suspected fibroadenomas are evaluated using mammography as it is 
more detailed and provides a more specific clue into the nature of the mass. Due to the 
density of a young female’s breasts, it is often difficult to view the mass with sufficient 
accuracy. Thus, in order to combat this drawback, ultrasound imaging became the most 
used diagnostic tool for discovering fibroadenomas in adolescents. While not as accurate 
or specific as mammography, studies have shown that sonography is sufficient enough to 
be used alone when strict criteria are met to diagnose a lesion as benign. Figure 7 
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illustrates the differences between the two imaging methods in regards to visible 
characteristics used to describe a lesion. 
 
Figure 7: Imaging Characteristics of Lesions. Table from Zonderland & Smithuis, 
2013. 
 Note ultrasound’s inability to accurately observe asymmetry, architectural 
distortion and calcifications when compared to mammogram [Figure 1]. 
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MAMMOGRAM 
 In women older than 35 years old, mammography is the most widely used 
imaging technique. This is further supported by the fact that mammography alone is 
sufficient to demonstrate lesion stability without other intervention due to its validity 
established over many studies (Graf et al., 2004). Ultrasound is now able to directly 
diagnose lesions as well, however only for a small amount of lesions that follow strict 
criteria such as small size, distinct encapsulation characteristic of fibroadenomas and lack 
of calcification or other complex elements. 
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Figure 8: Mammographic Image of a Breast Fibroadenoma. Adapted from Graf et al., 
2004. 
 Figure 8 shows an example image of a fibroadenoma that is clear enough to be 
sufficient evidence for diagnosis and conservative follow-up.  
 
ULTRASOUND 
 Ultrasound, as opposed to mammography, does not use ionizing radiation and 
captures real-time, non-invasive images (ACR, n.d.). It is usually painless, can be 
completed in less than 30 minutes, is widely available, and is significantly cheaper than 
other method. US imaging is relatively easy to use for radiology techs and physicians, 
however it requires an expertise in breast US for accurate detection, as the images are 
captured in real-time and masses may be missed if not properly recognized (ACR, n.d.).  
US imaging has been shown to be a confident diagnostic tool for both benign and 
malignant solid breast masses without additional intervention such as biopsy. Studies 
done by Stavros et al. (1995) and others have shown nearly a 99% accuracy rate in its 
predictive capabilities (Vade, Lafita, Ward, Lim-Dunham, & Bova, 2008); however, US 
remains limited in its ability to differentiate between fibroadenomas and phyllodes 
tumors, which are potentially malignant and typically category 4 or even category 5 
lesions (Yilmaz, Sal, & Lebe, 2002). Ultrasound imaging also provides limited visibility 
of many cancers and calcifications, however in regards to adolescents this limitation is 
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not as significant as the incident rate for cancers or calcifications are very low in this age 
group.  
While limited in its ability to tell solid masses apart, ultrasound excels in its 
ability to detect cystic masses and is often used along with the fine needle aspiration 
(FNA) biopsy technique (Yilmaz et al., 2002). The advantages it provides as a guidance 
technique over mammography, x-ray or MRI includes accessibility of all areas of the 
breast and axilla, real-time visualization of the needle, multi-directional sampling, lack of 
ionizing radiation, low cost and patient comfort (Helbich, Matzek, & Fuchsjäger, 2004). 
It is becoming more standard to use ultrasound-guidance during biopsy techniques, as 
well as minimally invasive treatments.  
Traditionally for breast ultrasounds, B-mode sonography, also known as 2D 
mode, is used during procedures (Schueller, Schueller-Weidekamm, & Helbich, 2008). It 
is called 2D sonography because it transmits the signal in a single direction, giving a flat 
image. Studies have also shown that other ultrasound modes may be useful for specific 
purposes, such as Tissue Harmonic Imaging (THI) or Compound Imaging (CI). THI is 
designed to visualize the lesion against a fatty background but is not very useful in 
visualizing needles used in biopsy (Mesurolle, Bining, El Khoury, Barhdadi, & Kao, 
2006; Sehgal, Weinstein, Arger, & Conant, 2006). It increases the signal-to-noise ratio, 
causing the lesion to be more hypoechoic and thus darker in contrast to the surrounding 
breast tissue, thus improving lesion detectability (Cha et al., 2007; Helbich et al., 1999; 
Saleh et al., 2001). CI is also able to enhance visibility of the lesion, though against a 
glandular background as opposed to a fatty one. It is also more adept at visualizing the 
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needles used in biopsy when compared to THI (Mesurolle et al., 2006; Sehgal et al., 
2006). It works by taking multiple frames of different frequencies and angles and 
combining them into a single image to better visualize the lesion margins and internal 
architecture (Mesurolle et al., 2006). Figure 9 shows an example of B-mode sonography 
versus THI. Note B-mode sonography reveals a clearer image of the biopsy needle, 
pointed out by the arrowhead. In contrast, THI shows a clearer image of the 
fibroadenoma, pointed out by the arrows, with sharper margins and contrast between the 
lesion and surrounding breast tissue.  
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Figure 9: Comparison between B-mode Sonography and THI. (A) B-mode 
sonography depicting better visualization of the biopsy needle. (B) THI depicting better 
visualization of the fibroadenoma. Figure adapted from Schueller et al., 2008.  
 
If the lesion were within a glandular region of the breast, CI imaging would be 
used instead of THI. 
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BIOPSY 
 With the modern push for conservative management in female adolescents, 
biopsy is not utilized as often as it was in the past. However, biopsy is often indicated 
when a lesion is categorized in BI-RADS as category 4 or category 5, resulting in a level 
of risk that is too high to simply passively monitor (Graf et al., 2004; C. A. Park et al., 
2006). In young females the discovery of a category 4 or category 5 lesion is unusual and 
fairly rare, though such a discovery would almost certainly result in an automatic request 
for biopsy. Unless circumstance requires it as previously discussed, biopsies on young 
females are typically avoided as they may cause iatrogenic risks on the developing 
breasts, resulting in possible aesthetic deformity (Chung et al., 2009; Lee & Soltanian, 
2015). Even the smallest of procedures may potentially cause damage, thus it is critical to 
weigh all the options prior to deciding whether to go ahead with further intervention or 
just observe (Lee & Soltanian, 2015). Should biopsy be deemed necessary, or at the 
request of the patient or her family, there are several techniques that can be utilized. 
There is the traditional open biopsy, which is quickly losing popularity particularly in this 
age group, FNA, and other emerging percutaneous techniques that are minimally 
invasive. 
 
OPEN BIOPSY 
 Open biopsy, or surgical biopsy, of fibroadenomas has been reported to account 
for approximately 50% of total open surgical biopsies (Greenberg, Skornick, & Kaplan, 
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1998). Open biopsy is traditionally the most commonly used biopsy method for 
adolescents; however there have been large pushes towards alternatives as the biopsy 
creates an additional surgery that may ultimately damage developing breast tissue. Aside 
from direct requests from the patient or the family, open biopsy is typically reserved only 
for solid lesions that are very large, have no regression on follow-up, are suspicious for 
malignancy, show progressive growth in patients with a known history of primary 
malignant tumors, or for patients with a family history of cancer, especially that of the 
breast (Ezer et al., 2013; Jawahar et al., 2015). The procedure involves an incision made 
into the breast tissue from which either a small portion of the lesion is removed, also 
known as ‘incisional biopsy,’ or the entire lesion is removed, or ‘excisional biopsy’ 
(Johns Hopkins Medicine Health Library, n.d.). If the lesion is small, deep or otherwise 
difficult to locate, then a technique called ‘wire localization’ may be used. In this 
technique, a special wire is placed into the lesion during surgery to locate the lump under 
x-ray guidance (Johns Hopkins Medicine Health Library, n.d.). These types of lesions are 
typically difficult to locate on imaging devices, particularly if obscured by other masses 
or densities, thus warranting open biopsy rather than needle biopsies (“Breast Biopsy,” 
Choosing Wisely, 2014). The cost of the procedure itself can range from anywhere 
between $750 - $1,200 depending on the region, however it often includes an additional 
charge for anesthesia, bringing the total up to approximately $2, 500 - $3,500 (“Biopsy 
procedures of breast, insured,” FH Consumer Cost Lookup, 2016). While the procedure is 
often insured, it can still include a considerable out-of-pocket cost that many families 
may be unable to afford, particularly if there are multiple lesions or lesions in both 
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breasts. Open biopsy is the preferred method of biopsy for patients with juvenile giant 
fibroadenomas as other methods are currently not as efficient in sampling the large mass; 
juvenile giant fibroadenomas are also associated with other skin deforming effects, such 
as skin dimpling or nipple inversion, that make sampling difficult with other methods (C. 
A. Park et al., 2006).  
 Aside from the mentioned exceptions, surgical biopsy is often avoided if possible 
due to the cost, time spent and subsequent cosmetic damage the procedure may induce. 
During the biopsy the physician is required to cut into the breast to take out large pieces 
of suspicious tissue. This may lead to bleeding, wound infection, longer recovery times, 
scars or even distortion of the breast tissue (“Breast Biopsy,” Choosing Wisely, 2014). In 
young adolescents, unless paired together with lumpectomy or other surgical removals, 
open biopsies should be avoided.  
 
FINE NEEDLE ASPIRATION 
 FNA is a type of percutaneous biopsy that involves placement of a very thin 
needle into the lesion or suspicious area in question to remove a small sample of the fluid 
and/or tissue in the area (Johns Hopkins Medicine Health Library, n.d.). It does not 
require an incision, has reduced morbidity, quicker procedure time and less side effects or 
complications in comparison to surgical/open biopsy (Lacambra et al., 2012). As its name 
implies this technique is particularly adept at aspirating fluid out of cysts or other fluid 
collections during the biopsy procedure (Helbich et al., 2004), an advantage that removes 
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an additional step that would have otherwise been taken in the treatment process. Upon 
the introduction of other percutaneous biopsy techniques, FNA is no longer considered 
the standard of care for benign breast lesions such as fibroadenomas; however it is often 
used for cysts. The reason for this includes the procedure’s many flaws, including 
difficulty in differentiating between fibroadenomas and phyllodes tumors (Celik et al., 
2015), particularly when complex fibroadenomas are involved (Ohashi et al., 2015). 
Atypical elements within complex fibroadenomas result in erroneous diagnoses of 
fibroadenoma lesions, having a higher chance of falling into an ‘indeterminate’ or 
‘suspicious for malignancy’ categorization as compared to non-complex fibroadenomas 
(Ohashi et al., 2015). With the movement towards imaging detection and screening of 
early diseases or cancers there are more and more nonpalpable lesions being discovered 
in women; however, FNA is not as efficient as other percutaneous biopsy techniques in 
retrieving samples for diagnosis (Lacambra et al., 2012). While FNA is certainly still a 
viable technique, it has been overshadowed by advancements in the field (Helbich et al., 
2004). 
 
PERCUTANEOUS BIOPSY 
 Percutaneous biopsy is minimally invasive and designed to reduce the numbers of 
open biopsies for lesions such as fibroadenomas. Histologic testing of the samples 
obtained from biopsy offers sufficient evidence for diagnosis of benign breast lesions 
such as fibroadenomas, particularly when used in concordance with US or 
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mammography, and surgery may be avoided depending on the individual (Helbich et al., 
2004). On the other hand, if surgery is ultimately required or requested there will only be 
one invasive procedure done as opposed to both the open biopsy and open excisional 
surgery done in the traditional route (“Breast Biopsy,” Choosing Wisely, 2014). It has 
also been shown to have better accuracy and handling when compared to FNA, further 
solidifying its role in the field of breast biopsy. Two of the most used techniques in 
particular are Long/Large Core Needle Biopsy (LCNB) and Vacuum-Assisted Core 
Biopsy (VACB).  
 
Figure 10: Percutaneous Biopsy Instruments. White arrow: standard LCNB device. 
Black arrow: 8-gauge VAB device. Arrowhead: 11-gauge VAB device, rapidly becoming 
the preferred size for the biopsy procedure. Figure is adapted from Schueller et al., 2008.  
 
Both of these techniques involve the use of a hand-held device containing a 
spring-loaded mechanism with an attached needle that has a small compartment within it 
to store a ‘core.’ The ‘core’ is essentially the sample of tissue obtained during the 
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procedure [see figure 10]. Using this method, the sample sizes are large enough for 
appropriate histological analysis of the lesion and surrounding tissue, resulting in higher 
diagnostic accuracy and sensitivity (Lacambra et al., 2012). 
 
Table 3: Comparison of Diagnostic Accuracy between LCNB and VAB. PPV positive 
predictive value, NPV negative predictive value. Table adapted from Lacambra et al., 
2012. 
 
 
 
Percutaneous biopsy has two major drawbacks: underestimation of disease and 
history of false-negative results, particularly when complex fibroadenomas are evaluated 
 LCNB VACB 
False Positive 1 0 
False Negative 7 0 
True Negative 118 75 
True Positive 159 10 
Total 285 85 
PPV (%) 98  100 
NPV (%) 94 100 
Sensitivity (%) 96 100 
Specificity (%) 99 100 
Accuracy (%) 96 100 
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(Helbich et al., 2004). Underestimation of disease occurs when high-risk lesions or 
carcinoma are present in the breasts, however they are poorly characterized in the 
pathology of the sample retrieved from the biopsy and therefore a confident diagnosis 
may not be made (Helbich et al., 2004). Underestimation of disease can result in delays 
when diagnosing a more complex fibroadenoma as extensive analysis is used to rule out 
malignancy in suspicious lesions as the tissue histology appears less concerning. 
Underestimation may be caused due to the location from which the sample was obtained, 
meaning multiple samples are often required. The rates of false-negative and false-
positive results in these two percutaneous methods were evaluated by Lacambra et al., 
(2012; Table 3).  Their study involved comparing the diagnostic accuracies and 
sensitivity of LCNB and VACB, with special emphasis placed on false-negative results.  
Of note, VACB was shown to have higher diagnostic accuracy with little to no evidence 
of false-negative or false-positive results. This is most likely because VACB techniques 
involve multiple samples being retrieved at once, allowing a larger and more 
comprehensive view of the lesion in question in comparison to LCNB. 
While fibroadenomas with complex elements or epithelial abnormalities typically 
require excision, many fibroadenomas that are diagnosed as benign by core biopsy are 
eligible for conservative follow-up due to the negligible incidence of malignancy 
regardless of the false-negative results (Sanders & Sara, 2015).  
 
LONG-CORE NEEDLE BIOPSY 
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 LCNB procedures involve removing small samples of breast tissue with the use of 
a hollow ‘large-core’ needle and spring-loaded mechanism (Lacambra et al., 2012). It 
may be done manually where the lesion is fixed with one hand, with stereotactic 
mammography where the breasts are compressed and held in place by a machine, or with 
US image guidance (Lacambra et al., 2012). The biopsy device contains a spring-loaded 
system with a single needle, meaning only one sample can be obtained each time the 
device is inserted (Lacambra et al., 2012). To have a sufficient amount of breast tissue for 
analysis, multiple samples are taken by the device that may result in bruising of the breast 
tissue, however the bruising typically resolves in a few days.  No incision is necessary for 
the procedure, meaning there is no chance of the patient developing scars or marks on the 
surrounding breast tissue as a result of the biopsy (“Breast Biopsy,” Choosing Wisely, 
2014). When compared to open biopsy, LCNB is faster, involves less patient discomfort, 
and has better cosmetic outcomes with no scarring in subsequent mammograms when the 
patient is older (“Breast Biopsy,” Choosing Wisely, 2014; Mainiero et al., 2002). It has 
also been shown to yield more tissue for better diagnostic accuracy and ancillary studies 
when compared to FNA, as well as allow assessment of stromal invasion from malignant 
lesions that would otherwise not be depicted (Lacambra et al., 2012). Depending on the 
region LCNB procedures may cost anywhere between $500 to $200 without insurance, 
approximately 56% less than open biopsy (“Biopsy procedures of breast, insured,” FH 
Consumer Cost Lookup, 2016; Liberman, 2000). This cost is even lower if US-guided 
LCNB is used as opposed to the stereotactic method, which involves obtaining x-ray 
imaging throughout the procedure for accuracy (Liberman, 2000). LCNB, whether using 
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US or stereotactic methods, is also a simple enough procedure where it can be done 
within a radiology or breast-imaging center, or in the doctor’s office (“Breast Biopsy,” 
Choosing Wisely, 2014).   
 As was previously mentioned, percutaneous biopsies in general have a small risk 
of false-negative results. With LCNB the risk has been determined to be approximately 
within 0-9% (Schueller et al., 2008). Reasons for these results have been shown to arise 
from multiple elements, including technical difficulties, which results in inaccurate tissue 
sampling (Schueller et al., 2008). These difficulties may arise from targeting errors due to 
poor lesion or needle visualization (particularly if no imaging is used in accompaniment 
with the procedure), lesion mobility upon compression, deeply located lesions, central 
lesions in a large breast, dense fibrotic tissue resistant to needle traversing, small sized 
lesions under 5mm, or poor lesion visibility due to small pools of blood formation after 
the needle punctures (Schueller et al., 2008). Another difficulty to note with the 
adolescent population in particular is movement or noncompliance with the procedure 
(Schueller et al., 2008) due to fear, lack of trust with the provider, or other situations that 
may make the patient uncomfortable or irrational. Younger pediatric patients in particular 
may be negatively impacted by the procedure and undergo psychological or emotional 
distress (Sosin et al., 2015). It is important to explain the procedure at length with the 
patient and their guardians to ensure an understanding before undergoing biopsy, as well 
as involve the guardian throughout the procedure for emotional support. If required, and 
available, procedural sedation is also recommended for cases such as these. LCNB, 
similar to FNA, also has difficulties in obtaining calcification samples as they are almost 
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always performed in solid masses. This may lead to underestimation of disease and holds 
a potential for false-negative results (Schueller et al., 2008).  
 LCNB procedures may be complimented by US or stereotactic maneuvers, 
allowing for more accurate and specific retrieval of samples. In particular, 3D US-guided 
LCNB has been shown to allow a better comprehension of topography, which in turn 
reduces the number of false-negative results (Lell, Wenkel, Aichinger, Schulz-
Wendtland, & Bautz, 2004; Surry et al., 2002; Weismann, Forstner, Prokop, & 
Rettenbacher, 2000). 3D US-guided LCNB is accomplished with a multi-planar 
transducer that allows for precise post-firing positioning, meaning the number of samples 
that are needed for a reliable diagnosis may be reduced (Lell et al., 2004; Surry et al., 
2002; Weismann et al., 2000). With stereotactic maneuvering the patient lies prone on a 
special table that has a hole near the middle for the breast to extend through, which is 
then compressed against the image acquisition device. A probe is inserted between the 
breast and the x-ray tube that will take still-image captures throughout the procedure to 
ensure accuracy (Wunderbaldinger, Wolf, Turetschek, & Helbich, 2002). While these 
tables are fairly expensive, they allow for more working room, decreased likelihood of 
patient motion and create a barrier between the patient and the procedure, often 
alleviating some of the stress involved.  
 
VACUUM-ASSISTED CORE BIOPSY 
 VACB, also referred to as the Mammotome breast biopsy system or ATEC 
(Automated Tissue Excision and Collection), is one of the newest procedures to emerge 
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onto the breast biopsy field (Johns Hopkins Medicine Health Library, n.d.). While the 
initial insertion of the needle is the same procedure as LCNB, VACB differs in that the 
probe contains a vacuum that draws tissue in from a side hole. After the sample is 
obtained, instead of retreating to prepare for the next insertion, a rotating blade advances 
over the tissue and cuts a core from the breast and withdraws the specimen, making room 
for another. Thanks to this method the device only needs to be inserted once to obtain 
multiple samples, though there is a slightly increased risk of a developing hematoma 
post-procedure when compared to LCNB (Schueller et al., 2008). However, this risk has 
been shown to be less than 1% (Gwinnett Medical Center Imaging, n.d.-c) and there is 
little to no architectural distortion or other characteristic changes to the breast that may 
otherwise be present in open biopsy (Huber, Wagner, Medl, & Czembirek, 2003). The 
cost to purchase an 11-gauge VACB device (which is the most commonly used size) is 
approximately 10 times greater than purchasing a LCNB device, though the procedure 
itself is still less expensive than surgical biopsy and approximately 71% faster, according 
to some studies (Alonso-Bartolomé et al., 2004). VACB shares with LCNB the 
difficulties with adolescents during the procedure, and has been reported to be more 
successful with adults for this reason. 
 In a study done by Lacambra et al. (2012), it was shown that in VACB the 
diagnostic accuracy is independent of the number of cores sampled, however in LCNB 
the accuracy correlates positively with the number of cores sampled. This discrepancy 
between the number of samples required can be due to the fact that VACB allows for 
larger samples with more accurate tissue acquisition, as the probe does not need to be 
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removed and reinserted (Ouyang et al., 2015; Schueller et al., 2008). The larger samples 
allow for a reduction in underestimation of disease or false-negative rates, which is as 
low as between 0-2.6% for VACB (Schueller et al., 2008). It is also more sensitive in 
detecting any underlying malignancy in non-palpable breast lesions upon analyzing the 
sample acquired (Lacambra et al., 2012). The larger samples sizes also point to a 
possibility of completely removing the benign lesion during the procedure when under 
local anesthesia, removing the need for surgery altogether (Fine et al., 2003). This notion 
is also the reason why VACB is more capable of detecting  calcifications in both palpable 
and nonpalpable lesions, further lowering the rates of underestimation and increasing the 
diagnostic accuracy (Choo et al., 2008; Li, Wang, Su, Liu, & Tang, 2010; Penco et al., 
2010; Su et al., 2010).  
 As with LCNB, there are multiple imaging techniques that may be used alongside 
VACB, including US, stereotactic maneuvering, and Magnetic Resonance Imaging 
(MRI). Of these US-guided VACB is the most commonly used technique, especially with 
adolescents, however there may be situations that warrant stereotactic maneuvering or 
MRI as well. The US-guided method is preferred as it is faster, less expensive, avoids 
ionizing radiation and allows samples to be retrieved from otherwise hard-to-reach areas 
such as the axillary region. US imaging is also done in real-time, meaning the radiologist 
may follow the motion of the biopsy needle as it moves through the breast tissue 
(Gwinnett Medical Center Imaging, n.d.-c). MRI-assisted VACB is typically performed 
when the lesion, or abnormal area, is non-palpable and not able to be seen on 
mammogram or ultrasound. It uses a high-powered magnet to guide the probe to the site 
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of the abnormal growth. The procedure is generally not painful and has results that are as 
accurate as when the tissue is removed surgically. It may be performed in an outpatient 
imaging center (Gwinnett Medical Center Imaging, n.d.-a). Stereotactic maneuvering in 
VACB is typically used when imaging shows a breast abnormality such as suspicious 
masses, microcalcifications, distortion in the structure of the breast tissue, or a new 
area/mass of calcium deposits present at previous surgery sites. The method is the same 
for that used in LCNB (Gwinnett Medical Center Imaging, n.d.-b).  
 The procedure is rarely painful due to local anesthesia, though it does carry a risk 
of infection or puncturing of the chest wall if the lesion is located very deep in the tissue, 
though this is very rare. Recovery time is brief and any post-procedure pain is controlled 
with non-prescription pain medication (Gwinnett Medical Center Imaging, n.d.-c).  
 
OTHER TEQNIQUES IN DEVELOPMENT 
To this day other techniques are constantly being studied, including the most 
recent to be published called ‘ductal lavage’ from “Breast Biopsy” in the Johns Hopkins 
Medicine Health Library. The technique is still under investigation, however it is directed 
towards women who show no symptoms but have a high risk for breast cancer. It 
includes a small catheter being inserted through the nipple into the milk duct of the 
breast, where saline is gently flushed through. It is then withdrawn back through the 
catheter along with a collection of ductal cells in the fluid that are subsequently examined 
for cancer, precancerous changes or benign breast lesions such as fibroadenomas.  
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CONSERVATIVE MANAGEMENT 
 Conservative management is a method reserved for benign fibroadenomas that are 
asymptomatic, not of significant size or rapidly enlarging, do not cause cosmetic 
distortion, lack complexity or have any other risk factors that may indicate malignancy in 
the near future (Lee & Soltanian, 2015). Conservative management involves annual or bi-
annual follow-ups with a provider with accompanying sonography and will only include 
surgery or other intervention is there is a significant change in the lesion, or if the family 
requests it (“Treatment Options for Fibroadenoma,” Breast Health Options, n.d.). Even 
upon request, however, it has been recommended to observe the lesions for at least 3-4 
months prior as there is a chance it may regress on its own (Lee & Soltanian, 2015). If the 
lesion is less than 3cm in size and does not expand in volume greater than 16% from the 
initial size, biopsy will not be necessary (Jawahar et al., 2015). Studies have shown that 
short-term follow up of every 6 months or 12 months is less expensive than a one-time 
procedure of needle biopsy by a factor of 8 (Helbich et al., 2004). This management 
method is particularly effective for young females with multiple fibroadenomas, 
particularly if they are of small size or even regress slightly. Removing all of the 
fibroadenomas in such females might entail the removal of surrounding, otherwise 
healthy breast tissue and may lead to scarring, disfiguration of the breast and other 
emotional trauma (ACS, 2015). Conservatively observing the masses with bi-annual US 
imaging is sufficient in most cases with the hope that the lesions regress in size on their 
own, or remain stable.  
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The conservative therapy method hinges on compliance with follow ups and 
sonography appointments to document stability (Grady, Gorsuch, & Wilburn-Bailey, 
2008), however a large number of women fail to do so due to financial or time restraints 
(Cant, Madden, Coleman, & Dent, 1995; Kaufman et al., 2002). Another proportion of 
women undergo surgical excision of their lesions or other interventional methods despite 
the demonstrated safety, either due to anxiety and discomfort or because the mass fails to 
regress or progressively enlarges (Cant et al., 1995; Dent & Cant, 1989; Dixon, Dobie, 
Lamb, Walsh, & Chetty, 1996; Greenberg et al., 1998b). With adolescents, conservative 
management may induce some anxiety, as the fibroadenoma will remain untreated, 
however it is important to effectively communicate the risks and benefits of treatment 
options, provide consistent reassurance that malignancy is rare in this population, and 
emphasize the importance of regular follow-up and imaging (Cerrato & Labow, 2013; 
Kaufman et al., 2002). However, despite multiple attempts of reassurance, discovery of a 
breast lump in an adolescent female will undoubtedly incite anxiety and concern for both 
the patient and the family (Cerrato & Labow, 2013). Teaching self-breast examinations 
for monitoring the size of the lesion may be ineffective, and may even backfire and 
induce obsessive behavior (Méndez Ribas, 2010). A reason for this is due to the average 
psychological state of a female adolescent; mammae are the most obvious secondary sex 
characteristics for these females, and it identifies them with their feminine role, socially 
positions them as women and may make them desirable to the opposite sex, something 
that is especially important in this age due to the excess of hormones in both sexes 
(Méndez Ribas, 2010). Slight alterations or deviations from what is considered ‘normal’ 
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cause a great deal of emotional and psychological stress, and often warrant requests for 
immediate fixes for the problem. This inhibits the use of the conservative method, as it 
will only cause further anxiety. Therefore during the decision making process for steps 
moving forward, patients or families that show continued signs of anxiety, regardless of 
the less than 1% chance of malignancy or risk of compromising breast development, 
should be offered the option for either excisional surgery or any other interventional 
method (Lee & Soltanian, 2015).  
 
PALPABLE VS NON-PALPABLE LESIONS 
One factor that may influence the decision to enter the conservative method is 
whether or not the mass in question is palpable or not. While it may not seem particularly 
important, follow up of a palpable mass with benign morphology may be more risky than 
follow up of a nonpalpable lesion (Graf et al., 2004). If a mass is revealed to be malignant 
with biopsy and it is already at a palpable size, the risk for metastasis and further 
complications are significantly higher (Tabár, Duffy, Vitak, Chen, & Prevost, 1999). A 
minimum of two years of follow up that have shown benign morphology and stable size 
of a nonpalpable mass is an accepted indicator of benignity (Graf et al., 2004). The 
amount of time required for palpable masses is longer due to the risks they carry. This is 
why it is essential for the patient to speak with his or her provider about the risks and 
chance of malignancy should they have a palpable mass to ease any anxieties that may 
appear (Graf et al., 2004).  
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 Data presented by Graf et al. (2004) has shown that cancer that has progressed to 
a palpable size but is still showing benign morphology is quite rare. Women with 
palpable abnormalities but negative results at both imaging (BI-RADS category 1) are at 
very low risk for cancer but they should still be followed up at short-term intervals. 
Furthermore, results of Graf et al.’s study indicate palpable, circumscribed, non-calcified, 
solid breast masses that are placed in BI-RADS 3 has the same probability of cancer as 
nonpalpable lesions in the same category, alleviating the urgency for biopsy and asserting 
probable benignity (Graf et al., 2004).  
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EVALUATION OF TREATMENT OPTIONS 
 Upon completion of imaging and diagnosis, as well as biopsy if warranted, the 
patient faces two options: the conservative method, or further intervention. While there is 
a modern push towards the conservative method with adolescents, intervention is 
recommended for fibroadenomas that are complex, greater than 5cm, rapidly increasing 
in size or causing considerable pain.  Moreover, the presence of a high risk genetic 
mutation or syndrome, cosmetic deformity of the breast or the existence of other risks 
towards normal development may suggest a treatment other than the conservative method 
(Jayasinghe & Simmons, 2009). These are all situations in which the conservative 
method may not be appropriate or will cause the patient, or family members, anxiety due 
to its associated risk that cannot be otherwise reassuring. Traditionally, when further 
intervention is recommended, the recommended method was open surgical excision to 
completely remove the fibroadenoma and some surrounding breast tissue. Similar to the 
situation with breast biopsy, there has now been an emergence of minimally invasive 
techniques that show great promise for safe, effective and cosmetic treatment of 
fibroadenomas (Lakoma & Kim, 2014). These techniques are targeted towards older 
patients with smaller fibroadenomas, typically less than 3-4cm (Matz et al., 2013); 
however they may be viable for adolescents as well. This includes endoscopic surgery, 
thermal and cryoablation, and the vacuum-assisted biopsy technique for removal of entire 
lesions. During the initial consultation between the patient and physician, discussions 
regarding which treatment option best suits the patient’s particular case of fibroadenoma, 
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as well as what they are most comfortable with doing, are done in order to get a clearer 
picture of the path ahead.  
Table 4: Comparison of Treatment Methods. Adapted by Nurko et al., 2005. 
 
Technique Open Surgical 
Excision 
Vacuum-
assisted excision 
Cryoablation Conservative 
Method 
Efficacy* Recurrence is 
‘infrequent’ 
98% at 6 
months 
54% at 6 
months; 65% at 
12 months 
38% 
Time to 
achieve effect 
Immediate Immediate 6-12 months 60 months** 
Patient 
Satisfaction 
Variable 92% at 6 
months 
91% at 6 
months; 88% at 
12 months 
Variable 
Requires prior 
biopsy 
No No Yes Recommended 
Typical 
location 
Outpatient 
Center 
Office Office Office 
Approximate 
cost 
$2,500 - 
$6,500 
Approximately 
$1,000 
$1,500 - $3,400 Minimal 
beyond initial 
biopsy, 
however it 
may increase 
over time with 
bi-annual 
physician 
visits and 
imaging 
*     Defined as the percentage of time a palpable lesion is converted to a nonpalpable 
lesion. 
**   Not all fibroadenomas regress on its own with time, this is reflected in the large time 
period. 
 
 Table 4 contains a simplified look into the four most commonly used treatment 
methods: open surgical excision, vacuum-assisted biopsy/excision, cryoablation and the 
conservative method. 
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OPEN SURGERY 
 Open surgical excision has been the most commonly used treatment method for 
fibroadenomas for a long time, particularly for adolescents. It includes the traditional 
lumpectomy, mastectomy for more extreme cases and the modern, less invasive method 
of endoscopic surgery.   
 
LUMPECTOMY 
 Lumpectomy, also known as partial mastectomy, is the most commonly used 
procedure for adolescents as it removes the lesion completely with a negligible rate of 
recurrence (Greenberg et al., 1998b). Once removed, the patient and her family will have 
peace of mind as the lesion will be removed and no longer a cause of concern despite its 
low chance of malignancy (Matz et al., 2013). The technique is recommended above all 
else for lesions that are particularly large, such as juvenile giant fibroadenomas, or have 
associated skin ulceration, musculoskeletal effects or significant psychological trauma in 
young females (C. A. Park et al., 2006). It may also be offered if the lesion is fixed to 
overlying skin or the nipple areolar complex, associated with axillary or supraclavicular 
lymphadenopathy (LAD) or if the lesion is especially tender (Divasta et al., 2012). The 
surgery removes the lesion as well as a small ring of surrounding normal breast tissue, 
however the goal is to avoid causing iatrogenic deformity to the breast whenever possible 
(Lee & Soltanian, 2015). When the lesion is smaller than 4cm the optimal incision site is 
circumareolar or in the inframammary crease, as these spots are the least visible for scar 
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formation and the most aesthetically pleasing (Cerrato & Labow, 2013; Méndez Ribas, 
2010). The post-operation check-up is approximately 4-8 weeks after the surgery in order 
to check the incision site for any damage, scarring or underlying infection (Cerrato & 
Labow, 2013). After this the patient may be checked bi-annually to re-assess for any 
recurrence or lesion formation in another spot (Cerrato & Labow, 2013). Once the breast 
tissue has stabilized over 2 years there may only be an annual screening if the patient so 
chooses.  
Open surgical excision is one of the most expensive procedures, coming at around 
an average of $2,500 – $6,500 depending on region and number of lesions being 
removed. The surgery itself may only cost as little as $1,000-$2,500 however it requires 
the use of general anesthesia or procedural sedation, increasing the total cost a significant 
amount (“Lumpectomy, insured,” FH Consumer Cost Lookup, 2016). If the patient has 
multiple fibroadenomas on the bilateral breasts being removed the cost may also increase, 
at times even doubling, due to the increased procedure time and labor involved.  
As breast fibroadenomas are almost always completely benign, the main goal of 
treatment is cosmesis and avoidance of iatrogenic injury as it may hinder breast 
development or cause breast asymmetry (Lee & Soltanian, 2015). Open surgical excision, 
while effective in removing the lesion, has an unfortunate side effect of causing visible 
scars that may result in contour deformities (Grady et al., 2008). It may also result in loss 
of breast volume, nipple areolar distortion or displacement or other changes in the shape 
of the breast depending on the size of the fibroadenoma being removed (Lakoma & Kim, 
2014; “Treatment Options for Fibroadenoma,” Breast Health Options n.d.). These are all 
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especially problematic for females with multiple breast fibroadenomas, particularly if 
they are bilateral, as they may be facing multiple surgeries and scars if the lesions 
continue to expand (Grady et al., 2008; Kaufman et al., 2002). Those that undergo one 
surgery are often hesitant to do another, for fear of more scars or increased damage to 
their breasts (Kaufman et al., 2002). Ultimately, for adolescent females with developing 
breasts the risks often outweigh the benefits of surgery if there are no other complications 
that necessitate the immediate removal of the lesion (Cerrato & Labow, 2013).  
 
SPECIFICS TO JUVENILE GIANT FIBROADENOMA 
  
While the procedure is typically not recommended for most benign 
fibroadenomas, adolescents with juvenile giant fibroadenomas have few other options 
when it comes to treatments. With larger lesions like these, treatments that also remove 
surrounding breast tissue may be unavoidable and necessary (Grady et al., 2008), leaving 
open surgical excision the treatment of choice for giant fibroadenomas (Lee & Soltanian, 
2015). As these lesions exhibit rapid growth it is crucial to remove them as soon as 
possible to avoid any physical or psychosocial damage. For giant fibroadenomas the goal 
of open surgical excision is to preserve the breast parenchyma and nipple areolar 
complex as much as possible in order to achieve superior aesthetic results (Sosin et al., 
2015). In order to combat poor cosmesis there are three commonly used approaches to 
surgery, as well as the option for reconstruction after removal. The periareolar approach 
is simple and leaves the least visible scar as it blends in with the tissue of the areola; 
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however it is associated with loss of sensation of the nipple (C. A. Park et al., 2006). The 
inframammary approach is the most commonly used as it provides good exposure for 
removal and the scar is less visible in the crease, however it limits the correction of 
additional deformities (C. A. Park et al., 2006). The inverted ‘T’ incision, or ‘anchor,’ 
provides excellent exposure for removal of mastopexy, or breast lift, if necessary (C. A. 
Park et al., 2006). It involves the areola, inframammary crease as well as a line straight 
down in between them, leading to the most noticeable scar.  
As juvenile giant fibroadenomas more often than not result in significant breast 
volume loss and deformity, a key element in excision is also reconstruction of the breast. 
There is current debate on whether to reconstruct the breast at the same time as the 
lumpectomy or to do it after a period of time. Many surgeons recommend waiting up to a 
year after the lumpectomy for the ptotic breast skin envelope to retract before doing any 
further surgery (Chepla et al., 2011). Once the skin has retracted, it will be easier to 
restore the breast shape and remove the need for further reduction or augmentation 
(Chepla et al., 2011). However, if the skin envelope is distorted significantly by the size 
of the giant fibroadenoma, skin retraction is unlikely and it may cause significant distress 
to the patient (Lee & Soltanian, 2015). In order to improve patient satisfaction and avoid 
poor cosmesis, reshaping techniques such as mastopexy and reduction were employed at 
the same time as the initial excision of the fibroadenoma (Lee & Soltanian, 2015). A 
study by Chepla et al., (2011) has shown that this immediate technique results in a 
superior outcome with stable long-term results. It also minimizes subsequent surgeries 
and reduces the psychosocial comorbidity that is associated with the waiting period due 
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to the postoperative appearance of the breast. However if something goes wrong during 
the reconstruction, either due to technique or unwanted skin retraction post-procedure, 
the backlash will be two-fold as it may include a compromised aesthetic result or breast 
asymmetry, resulting in further surgery and the loss of the benefit to this approach (Sosin 
et al., 2015).  
 
MASTECTOMY 
 Mastectomy, or total removal of the breast, is an extreme measure against a breast 
fibroadenoma that is commonly reserved only for unusual or recurrent giant 
fibroadenomas that cause significant distress (Park et al., 2006). While reconstruction 
will more than likely follow the procedure, it is a daunting surgery that is not typically 
recommended for adolescents for the anxiety it may cause. If it must be done, immediate 
reconstruction is frequently recommended in order to limit the number of procedures and 
psychosocial consequences of the breast deformity (Park et al., 2006). 
 
ENDOSCOPIC SURGERY 
 Endoscopic surgery is a variation of open surgery, as it utilizes 3 small incisions 
in the mid axillary line as opposed to a large incision in the center of the breast (Lee & 
Soltanian, 2015). The fibroadenoma is dissected from the surrounding tissue through an 
endocatch bag that is inserted into the breast, where lesions smaller than 3cm is pulled 
directly through the larger incision into the bag and lesions larger than 3cm are cut within 
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the bag removed piecemeal (Lakoma & Kim, 2014). Postoperative complications include 
subcutaneous emphysema to the neck or a small skin burn; however, the procedure has 
been shown to yield excellent cosmetic results, approximately 89.5%, with small scars 
that are not on the breast itself and easily concealed by the arm (Lakoma & Kim, 2014). 
Juvenile giant fibroadenomas are also able to be removed using the endoscopic 
technique, though it requires a periareolar incision instead of the 3 small incisions in the 
mid-axillary line (Lakoma & Kim, 2014). 
 
MINIMALLY INVASIVE ALTERNATIVES 
 Minimally invasive alternatives were developed in order to combat the flaws of 
open surgical excision. The goal of minimally invasive alternatives is to provide 
treatment options that are effective, fast, and have the best cosmesis possible in order to 
ensure psychosocial stability after the procedure. While many of the current techniques 
are targeted towards adult females, typically older than 35, they may also be used on 
adolescents. As these techniques generally do not require procedural sedation, they may 
cause stress on the adolescent and trigger anxiety that will be counterproductive. 
Generally, explaining the procedure in the initial consultation with the adolescents and 
their families give a good indication on whether or not the minimally invasive 
alternatives are appropriate to use.  
 
 60 
 
VACUUM-ASSISTED EXCISION 
 Vacuum-assisted excision (VAE) is the same procedure as vacuum-assisted core 
biopsy, however in this case the goal is not to retrieve tissue samples but to remove the 
lesion in its entirety. Its advantages over VACB include reduction of sampling error, 
decreased likelihood of histological underestimation or imaging-histological discordance, 
and decreased re-biopsy rate (H.-L. Park & Kim, 2011). It is minimally invasive and uses 
the assistance of imaging, meaning it is able to remove all image-based evidence of a 
lesion up to 3cm in size (Fine et al., 2002; Lee & Soltanian, 2015; Ouyang et al., 2015). 
Lesions less than 2cm in size have been shown to be associated with complete removal 
and negligible chance of recurrence in various studies (Lee & Soltanian, 2015). For 
women that are uncomfortable with or deny conservative management, VAE is an 
effective alternative that leaves no scars and requires little to no follow-up after the 
procedure (Grady et al., 2008). For benign breast lesions like fibroadenomas it has the 
potential to replace open surgical excision, especially for older females (Grady et al., 
2008). Studies with 6-month follow ups revealed VAE is associated with high patient 
satisfaction and reduced levels of anxiety when compared to open surgical excision (Fine 
et al., 2003). The only known side effects of the procedure are the same as VACB- a 
small ecchymosis, approximately 0-13% chance for hematoma formation and 40% 
chance for mild pain that may be treated with over the counter acetaminophen (Grady et 
al., 2008).  
 VAE’s ability to completely remove lesions and its chance for recurrence has 
been a topic of controversy for many years. Lesion remnants have been found post-
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procedure in the surgical excision site in some studies (Reiner et al., 2009), leading 
surgeons to believe that it is not a viable procedures for patients with a malignant lesion 
or breast cancer (Lakoma & Kim, 2014); however, residual, nonpalpable masses are often 
not a concern for benign breast fibroadenomas. It has been suggested that VAE not used 
as a treatment measure on its own to combat this risk, even in the case of complete 
removal of microcalcifications (Penco et al., 2010). There are several possibilities for 
residual masses, including the following: local anesthesia or hematoma masked the 
ability of US to image the entire lesion at the time of the procedure or the residual mass is 
due to post-procedural scarring or fibrosis (Fine et al., 2003). It was also initially thought 
that the initial mass was not completely removed and resulted in the residual mass; 
however recent studies have shown that it may in fact be due to an additional mass that 
was initially too small to be detected using imaging during the procedure that has grown 
and caused a new lesion (Ouyang et al., 2015). This is backed by further evidence with 
malignant lesions, showing that often the recurred lesion has no evidence of residual 
disease (Grady et al., 2008 and Ouyang et al., 2015).  
 The relapse rate for patients with any benign breast disease in a study using 1,578 
participants has been reported to be approximately 4% subsequent to VAE treatment 
(Ouyang et al., 2015). The overall recurrence rate has been reported to be approximately 
33% after 60 months for fibroadenomas specifically (Grady et al., 2008). It has been 
shown that fibroadenomas that were initially less than 1.5 – 2cm in diameter were 
successfully excised with little to no chance for recurrence after a period of up to 2 years 
(Grady et al., 2008; Sperber et al., 2003). Most, if not all recurrences were shown to be 
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with fibroadenomas that were originally more than 2 cm in diameter, suggesting that 
larger lesions require supplementary treatment (Grady et al., 2008). 
 
Figure 11: Percentage of Fibroadenoma Recurrence using US-Guided VAE. Figure 
taken from Grady et al., 2008. The y-axis depicts the percentage of recurrence in 
decimals. 
 Figure 11 shows the results of a study done by Grady et al., highlighting the 
percentage of recurrence of breast fibroadenomas after 60 months. As the initial sightings 
of recurrent lesions are shown to be around 10-11 months after the procedure it has been 
hypothesized that there may be an additional lesion that was too small to initially be seen 
using ultrasound. This lesion most likely grew in size and caused a relapse in these 
patients. Despite the risk for recurrence, VAE is still associated with high patient 
satisfaction.  
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ABLATION 
 Ablation has been a valid technique for tumors in other locations of the body 
including the liver, kidneys and lungs; however, it is relatively new to the field of breast 
lesions (Lakoma & Kim, 2014). Fibroadenomas are relatively superficial lesions and are 
especially suitable for minimally invasive ablation techniques (Kovatcheva et al., 2015). 
There are two types, thermal ablation and cryoablation, which utilize both extreme heat 
and extreme cold respectively. Thermal ablation of breast tissue is still being tested in the 
United States and not widely available; however, cryoablation has been FDA approved 
since 2001 (Lakoma & Kim, 2014). 
 
THERMAL ABLATION 
 Thermal ablation procedures use heat from three different sources: 
radiofrequency, high-intensity focused ultrasound and lasers. They function by causing 
tissue-wide necrosis of the targeted lesion and a rim of normal breast tissue around it 
(Dowlatshahi, Wadhwani, Alvarado, Valadez, & Dieschbourg, 2010). The coagulated 
tissue is then partially liquefied and aspirated like a cyst, and the lesion subsequently 
shrinks over time (Dowlatshahi et al., 2010). There may be internal scars that appear on 
mammogram; however this does not interfere with annual evaluations (Dowlatshahi et 
al., 2010). These procedures are typically done in outpatient centers under conscious 
sedation or local anesthesia if that patient so chooses, reducing costs compared to open 
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surgical excision (Kovatcheva et al., 2015). Thermal ablation procedures are effective in 
reducing the volume and clinical symptoms, if any, of breast fibroadenomas without any 
serious side effects (Kovatcheva et al., 2015). Radiofrequency ablation is the most 
popular as it has the ability to target lesions that are up to 3-5cm in diameter (Lakoma & 
Kim, 2014). High intensity-focused ultrasound are essentially non-invasive, making it a 
current subject of interest, however further studies are required to assess long-term 
efficacy (Kovatcheva et al., 2015). Laser ablation may be done in doctor’s offices under 
local anesthesia with minimal pain and discomfort (Dowlatshahi et al., 2010), though it 
may be more expensive than radiofrequency ablation.  
 Thermal ablation procedures may include side-effects such as superficial burns, 
hyperpigmentation over the treatment area, skin indurations, recurrence, incomplete 
removal and inability to obtain clear surgical margins (Lee & Soltanian, 2015). The 
technique may also cause considerable discomfort to some patients, requiring the use of 
conscious sedation or even general anesthesia (Kaufman et al., 2002). Radiofrequency or 
laser ablation techniques are poorly visualized on ultrasound for real-time monitoring as 
there are no visible changes occurring causing estimation of negative margins to be 
difficult (Lakoma & Kim, 2014). The patient is then at risk for thermal injury, which may 
include muscle or skin burns.  
 
 
CRYOABLATION 
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 Cryoablation uses extreme cold to completely destroy the tissue of the targeted 
lesion. Like thermal ablation, it is a less-invasive treatment compared to open surgical 
excision that does not result in mammographic changes, breast deformation or scarring 
(“Treatment Options for Fibroadenoma” Breast Health Options, n.d.). It has been used 
successfully in both adults and adolescents; however it is less common in adolescents 
(Cerrato & Labow, 2013; Jolesz & Hynynen, 2002; Kaufman et al., 2002). It is reported 
to be comfortable and painless, as the cold acts along with the local anesthesia to numb 
the area (“Treatment Options for Fibroadenoma” Breast Health Options, n.d.). The 
procedure is often completed in doctor offices and includes a small, 3mm incision that 
may be closed without sutures, resulting in no scars (Kaufman et al., 2002 and Chepla et 
al., 2011). A small probe is then inserted into the targeted fibroadenoma with the 
assistance of US through the incision site, where the lesion cells are destroyed with 
extremely cold temperatures, creating an ‘iceball’ that may be visualized in figure 12 
(“Treatment Option for Fibroadenoma” Breast Health Option, n.d.). The body then 
naturally absorbs the destroyed cells over time, which may vary depending on the initial 
size of the fibroadenoma (“Treatment Options for Fibroadenoma” Breast Health Options, 
n.d.). Lesions less than 2cm in size are associated with better outcomes in both 
reabsorption and non-palpability post-procedure (Nurko et al., 2005). Kaufman et al. 
conducted a study using 57 patients that had undergone cryoablation therapy in the past 
12 months, collecting data on the reduction size of their lesion, shown in figure 13. They 
reported that after six months approximately 65% of the lesion had reduced, while at 12 
months it had gone up to 92%.  
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Figure 12: Visualization of Iceball on Ultrasound in Cryoablation Procedure. Iceball 
containing fibroadenoma viewed on ultrasound. Note the fluid injected between the 
iceball and skin, used to prevent any further necrotic damage aside from the targeted 
lesion. Figure taken from Kaufman et al., 2002. 
 
 Cryoablation has several distinct advantages: excellent visualization under 
ultrasound permitting real-time monitoring and precise procedural control and skin 
protection that is not granted using thermal ablation (Lakoma & Kim, 2014), minor 
procedural and postoperative discomfort, excellent cosmesis without tissue removal and 
minimal scarring, and elimination of the need for sedation due to its inherent anesthetic 
properties (Kaufman et al., 2002 and Nurko et al. 2005). Of note, if a patient had multiple 
fibroadenomas adjacent to the initial target, they may be treated as one large lesion and 
treated simultaneously with a single pass of the probe (Kaufman et al., 2002). The 
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procedure usually takes approximately 10-15 minutes and the patient may return to 
normal activities very quickly post-procedure (“Treatment Options for Fibroadenoma” 
Breast Health Options, n.d.). As the destruction of the fibroadenoma is in situ, there is 
reduced risk of breast distortion or poor cosmesis, resulting in high patient satisfaction 
(Lee & Soltanian, 2015). Cryoablation is also less technically challenging when 
compared to VAE, making it easier on physicians to perform (Kaufman et al., 2002). 
 
Figure 13: Reduction of Lesion Size Post-Cryoablation. Figure taken from Kaufman et 
al., 2002.  
 
 As evidenced in figure 13, cryoablation does not provide immediate results, 
particularly for patients that have lesions larger than 2cm (Nurko et al., 2005). It is still a 
viable treatment option for larger lesions; however patients should be warned ahead of 
time that the mass may not fully resolve for several months after the cryoablation. While 
cryoablation generally costs less than open surgical excision, it is still currently one of the 
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more expensive alternatives in the market (“Treatment Options for Fibroadenoma” Breast 
Health Options, n.d.). Of note, insurances may cover the cost of the open surgical 
excision however, as cryoablation is still relatively new, it may not be covered and thus 
the patients are forced to pay out of pocket. 
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CONCLUSION 
 
ASSESSMENT OF MANAGEMENT AND TREATMENT COMBINATIONS 
 With the ever growing list of management and treatment options available for 
fibroadenomas, it is important to evaluate which methods are most effective for the 
specific type of fibroadenoma the patient has. Of particular interest are female 
adolescents, as there are more intricate details at play concerning psychosocial 
implications that need to be considered with as much importance as the effectiveness and 
reliability of any procedures or testing. 
 
SIMPLE FIBROADENOMA 
 Simple fibroadenomas are the most common variation of the disease, affecting as 
many as 70-90% of all cases (Lee & Soltanian, 2015). This is especially true with the 
adolescent population, as complications such as calcifications and other changes in breast 
tissue that signify malignancy are less common in the younger age groups. Simple 
fibroadenomas may be palpable or nonpalpable, however they typically do not cause any 
concerning cosmetic changes of the breast aside from the basic anxiety of having a lump 
in the breast due to their small size. As such, the most commonly accepted practice for 
these types of patients is the conservative method (Ng et al., 2011). Approximately 10-
40% of all cases regress spontaneously without any intervention (Jayasinghe & Simmons, 
2009), and many others remain stable without any concerning changes. For simple 
fibroadenomas in adolescents, avoiding any sort of invasive intervention, whether it is 
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simple biopsy or surgical excision, is the main goal as there will always be a chance of 
iatrogenic damage to the developing breast. While this method is ideal, there may be 
patients or family members that are unable to participate in the conservative method due 
to excessive anxiety despite all reassurances of the benignity of the disease. Further 
imaging, surveillance or biopsy may be ordered to build a case around the disease and its 
benign nature, however there may be times the patient and/or family are still 
uncomfortable with the conservative method. If this is the case, minimally invasive 
procedures are encouraged to avoid open surgery, as it may cause cosmetic damage and 
further aggravate the anxiety and stress the situation gives the adolescent. VAE or 
cryoablation are good techniques that may be used, however it is important to explain the 
process to the patient and family thoroughly to ensure the patient is able to undergo such 
a procedure. If there may be complications, however the patient and/or family members 
wish to go ahead with these methods, procedural sedation may be requested to make the 
situation less stressful. Open surgical excision should be reserved only for adamant 
requests and emergency situations. 
 
JUVENILE GIANT FIBROADENOMA 
 Juvenile giant fibroadenoma look remarkably similar to phyllodes tumors, which 
are most often malignant, thus imaging via US is strongly recommended along with 
tissue biopsy for histological evaluation (Sosin et al., 2015). The type of biopsy to be 
performed depends on the future treatment strategy, conservative or further invasive 
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intervention, which is to be discussed with the patient and the family prior to beginning 
any further intervention after the imaging. Observation may be recommended if the 
lesion is not causing significant cosmetic change or discomfort, or if the patient prefers to 
avoid any surgical procedures, however this is most often not the case with adolescents. 
Juvenile giant fibroadenomas typically cause enough cosmetic change to cause 
psychosocial implications for younger patients, and it is therefore recommended that 
excision be considered first. If surgical procedures are recommended, such as 
lumpectomy or mastectomy, biopsy procedures should be avoided to minimize any 
iatrogenic injuries or invasive procedures (Sosin et al., 2015). 
 
MULTIPLE FIBROADENOMA 
 Patients with multiple fibroadenoma, particularly adolescents, face a choice that is 
more difficult than other cases. It may be possible to excise each lesion as they appear, or 
grow; however, multiple procedures may lead to scarring, iatrogenic damage or other 
cosmetic deformities of the breast (Williamson et al., 1993). Another suggestion may be 
to treat the fibroadenoma conservatively, as if they were multiple simple fibroadenoma, 
granted the cytology and typical clinical/US appearance is consistent with a benign lesion 
(Williamson et al., 1993). This method will avoid multiple surgeries and complications 
for the patient, however as with simple fibroadenoma it may not ease the anxiety the 
patient has for the disease. Biopsy is certainly recommended in these patients as the 
multiple lesions may represent a risk for malignancy, albeit rare. LCNB is recommended 
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for adolescents, unless VAE will be performed as both a biopsy procedure and treatment 
option. Open surgical excision is to be avoided, as one excision may ultimately lead to 
several more that may cause more harm than benefit, or even deform the breast. Of the 
minimally invasive procedures cryoablation is particularly recommended, due to its 
ability to target multiple fibroadenoma at the same time without added excision or 
treatments. Procedural sedation may be required to ease any patient anxiety during the 
procedure; however, studies have shown cryoablation to be successful in adolescents, 
though not often done.  
 Patients with multiple giant fibroadenomas are left with few options, and most 
tend to undergo open surgical excision. There is also a high incidence of recurrence 
associated multiple giant fibroadenoma, though this rate may decrease as the patient 
becomes older (Musio et al., 1991). Faced with possibly multiple open surgical excisions, 
the most important factor in these patients are the reconstructions that are to be completed 
alongside, or after, the procedural excision. These reconstruction procedures may include 
reduction mammoplasty and simple mastectomy with reconstruction, though mastectomy 
is to be reserved for extreme cases (Musio et al., 1991). 
 
OPINIONS IN LITERATURE REGARDING FUTURE STUDIES 
 The general consensus for a treatment option for females, adolescent or older, 
with fibroadenoma is the less invasive and efficient, the better (Grady et al., 2008). 
Multiple trials are conducted testing various other alternatives to surgical procedures, 
with a few omitting invasive intervention entirely such as with high intensity-focused 
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ultrasound. As one of the largest concerns for the conservative method is long-term 
surveillance noncompliance and associated anxiety, it is important to emphasize as little 
post-procedural observation as possible. Techniques that limit recurrence and are able to 
completely remove the lesion are ideal, and something that is constantly being worked 
on. It is predicted that in the future conservative management will develop and ultimately 
replace open surgical treatment, particularly for female adolescents with benign 
fibroadenoma (El-Wakeel & Umpleby, 2003). Should the conservative method cause 
further anxiety, or is otherwise not accepted by the patient and/or family members, 
minimally invasive procedures such as cryoablation appear to be excellent alternatives 
that include minimal side-effects and have great cosmesis. The biggest downfall to this 
procedure is its long observation period and time to take effect, however if properly 
discussed with the patient and family members prior to the procedure it may not pose as 
much of a problem.  
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